» Articles » PMID: 39130872

Blood Viscosity Changes in Diabetes Mellitus: A 20-Year Bibliometric Review and Future Directions

Overview
Journal Cureus
Date 2024 Aug 12
PMID 39130872
Authors
Affiliations
Soon will be listed here.
Abstract

Changes in hematological parameters due to diabetes are reflected in changes in whole blood viscosity (WBV). Understanding the impact of diabetes and its cardiovascular disease (CVD) complications can provide substantiation of how laboratory tests for WBV are useful to monitor the progression and treatment. The review examines research work done in the past 20 years to provide a framework for the present agenda. This was a narrative review that followed the standard Scale for the Assessment of Narrative Review Articles (SANRA) approach. It includes both conceptual and empirical reviews. WBV was appraised in the context of bibliographic research on diabetes and other related factors such as metabolic syndrome (MetS) and oxidative stress. The association of abnormal erythrocytes as well as the relationship between WBV and MetS is established. Changes in diabetes that contribute to the development of diabetic cardiovascular complications occur through the pathway of WBV physiology. However, longitudinal analysis is very limited. There is a dearth of longitudinal study data on WBV in diabetes management. This lack of data justifies a need for further studies, especially prospective and retrospective analysis, to investigate the prevalence of diabetes mellitus about the prevalence of cardiovascular complications indices, especially estimated WBV (eWBV) between periods and within cohorts.

References
1.
. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

2.
Kearney-Schwartz A, Virion J, Stoltz J, Drouin P, Zannad F . Haemorheological disturbances in hypertensive type 2 diabetic patients--influence of antihypertensive therapy. Fundam Clin Pharmacol. 2007; 21(4):387-96. DOI: 10.1111/j.1472-8206.2007.00496.x. View

3.
Nwose E, Richards R, Butkowski E, Cann N . Position paper for health authorities: archived clinical pathology data-treasure to revalue and appropriate. Afr J Med Med Sci. 2011; 39(4):311-5. View

4.
Ridker P, Buring J, Cook N, Rifai N . C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003; 107(3):391-7. DOI: 10.1161/01.cir.0000055014.62083.05. View

5.
Nwose E, Jelinek H, Richards R, Kerr P . Erythrocyte oxidative stress in clinical management of diabetes and its cardiovascular complications. Br J Biomed Sci. 2007; 64(1):35-43. DOI: 10.1080/09674845.2007.11732754. View